Trials / Completed
CompletedNCT03336593
Protectivity and Safety of Quadrivalent Influenza HA Vaccine in Indonesian Population
A Bridging Study to Assess Protectivity and Safety of Quadrivalent Influenza HA Vaccine in Indonesian Population
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 810 (actual)
- Sponsor
- PT Bio Farma · Industry
- Sex
- All
- Age
- 6 Months – 40 Years
- Healthy volunteers
- Accepted
Summary
This study is to assess protectivity and safety of Quadrivalent Influenza Vaccine in Indonesian Population
Detailed description
To describe the protectivity rate of Quadrivalent Influenza HA vaccine 28 days after immunization in Indonesian population. To describe immunogenicity of quadrivalent Influenza HA vaccine in all subjects
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Quadrivalent Influenza Vaccine | 1 or 2 doses of Quadrivalent Influenza Vaccine depends on age |
| BIOLOGICAL | Trivalent Influenza Vaccine | 1 dose of Trivalent Influenza Vaccine |
Timeline
- Start date
- 2017-11-21
- Primary completion
- 2018-03-14
- Completion
- 2018-11-30
- First posted
- 2017-11-08
- Last updated
- 2019-04-02
Locations
3 sites across 1 country: Indonesia
Source: ClinicalTrials.gov record NCT03336593. Inclusion in this directory is not an endorsement.